The new oral hypoglycemic agent, CS-045, inhibits the lipid peroxidation of human plasma low density lipoprotein in vitro.
Several lines of evidence have revealed that the oxidative modification of low-density lipoprotein (LDL) is probably associated with the genesis of the atherosclerotic region. CS-045 is a new (thiazolidine) class of oral hypoglycemic agent which has a hindered phenol in the side chain (an analogue of alpha-tocopherol). The present results indicate that CS-045 had a relatively high antioxidative potency in inhibiting the lipid peroxidation of human plasma LDL in vitro induced by 2,2'-azobis(2-amidinopropane) dihydrochloride (AAPH) compared with that of alpha-tocopherol. These findings suggest that CS-045 may be useful in preventing the progression of atherosclerosis in diabetic patients.
Nagasaka
Y
Y
Department of Biochemistry, Yamaguchi University School of Medicine, Japan.
Kaku
K
K
Nakamura
K
K
Kaneko
T
T
D000284:Administration, Oral; D000578:Amidines / Q000037:antagonists & inhibitors; D002839:Chromans / Q000737:chemistry / Q000494:pharmacology*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D015227:Lipid Peroxidation / Q000187:drug effects*; D008077:Lipoproteins, LDL / Q000097:blood / Q000302:isolation & purification / Q000378:metabolism*; D013844:Thiazoles / Q000737:chemistry / Q000494:pharmacology*; D045162:Thiazolidinediones; D017392:Thiobarbituric Acid Reactive Substances / Q000032:analysis; D013997:Time Factors; D000077288:Troglitazone; D014810:Vitamin E / Q000494:pharmacology
D000578:Amidines; D002839:Chromans; D007004:Hypoglycemic Agents; D008077:Lipoproteins, LDL; D013844:Thiazoles; D045162:Thiazolidinediones; D017392:Thiobarbituric Acid Reactive Substances; D014810:Vitamin E; C046728:2,2'-azobis(2-amidinopropane); D000077288:Troglitazone